Always seek the advice of a medical practitioner before beginning any treatment
Viability assay was performed using CellTiter-Glo luminescent cell viability assay kit (Promega, WI)
Then, the trypsin/EDTA solution was neutralized with Dulbeccos modified Eagles medium (DMEM, #22320-022, ThermoFisher Scientific, Waltham, MA, USA), supplemented with 10% (v/v) fetal bovine serum (FBS, #S181C, Biowest, Nuaill, France)
Remarkable Results The findings were impressive: BPC-157 Only Group (12 patients): 11 out of 12 patients (91.6%) experienced significant improvement Only 1 patient (8.3%) saw no improvement BPC-157 + TB4 Combination Group (4 patients): 3 out of 4 patients (75%) showed significant improvement 1 patient (25%) experienced no relief Overall Success Rate : 14 out of 16 patients (87.5%) found relief from their knee pain What Makes BPC-157 Different from Traditional Treatments
Class: Small-molecule NNMT inhibitor (not a peptide)
[CrossRef] [PubMed] [Google Scholar] GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus